Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBaylor Scott & White Lyfgenia Coverage Prior Auth …
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 311

    Lovotibeglogene autotemcel (Lyfgenia) — Medical Coverage Policy

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 311 alerts

    Get alerted when Policy 311 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for one-time administration of lovotibeglogene autotemcel (Lyfgenia) for members with sickle cell disease, including eligibility, exclusions, and coding guidance; applies to Baylor Scott & White Health Plan lines of business.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyLovotibeglogene autotemcel (Lyfgenia) — Medical Coverage Policy
    Policy CodePolicy 311
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewAug 11, 2025
    Next Review DateJun 25, 2027
    Key ActionObtain prior authorization and submit documentation confirming age, genotype, performance status, hydroxyurea failure/contraindication, sVOE history, treatment center attestation, and required labs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    one per lifetimetreatment administrations considered medically necessary
    >=4sVOE history required
    12–50eligible age range
    required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    prior authorization
    J3394HCPCS updated

    Coverage Criteria

    Initial Therapy Criteria

    Covered when ALL of the following are met:

    Lovotibeglogene initial therapy criteria

    • Contraindication to exagamglogene: Member has a contraindication to exagamglogene (Casgevy) (provider documentation).
    • Lovotibeglogene is prescribed by or in consultation with a board-certified hematologist.
    • Member age is 12 years or older and less than or equal to 50 years.
    • Performance status is Karnofsky >= 60% for subjects >=16 years or Lansky >= 60% for subjects <16 years.
    • Member has a diagnosis of sickle cell disease (SCD) with genotype confirmed by molecular or genetic testing: βS/βS OR βS/β0 OR βS/β+.
    • Provider attests member will receive lovotibeglogene at an activated qualified treatment center.
    • Member has experienced hydroxyurea failure, intolerance, or has a documented contraindication to hydroxyurea.
    • Member is eligible for autologous hematopoietic stem cell transplant (aHSCT).
    • Member does NOT have an available HLA‑matched related donor.
    • Member has NOT previously received HSCT, lovotibeglogene, any other gene therapy for SCD, or investigational cellular therapy for SCD.
    • Lovotibeglogene will NOT be used concomitantly with other gene editing therapies for SCD.
    • Dosing and administration will follow FDA‑approved labeling.
    • Member experienced >= 4 severe vaso‑occlusive events (sVOE) in the prior 2 years while receiving appropriate supportive care (sVOE as defined in policy: acute pain events requiring facility visit and pain medications or RBC transfusion; acute chest syndrome with new pulmonary infiltrate and symptoms; priapism >2 hours requiring facility visit; splenic sequestration with enlarged spleen and >=2 g/dL hemoglobin drop; or acute hepatic sequestration with liver enlargement, RUQ pain, abnormal LFTs not due to biliary disease, and >=2 g/dL hemoglobin drop).

    Exclusion criteria that preclude coverage include specified laboratory abnormalities, organ dysfunction, infectious or immunologic conditions, family history, and treatment contraindications. Specifically, members are excluded for any of the following: absolute neutrophil count (ANC) <1 × 10^9/L (<0.5 × 10^9/L for subjects receiving hydroxyurea); platelet count <100 × 10^9/L; baseline left ventricular ejection fraction (LVEF) <45%; estimated glomerular filtration rate (eGFR) <70 mL/min/1.73 m^2; history of iron overload or serum ferritin >1000 ng/mL with cardiac MRI T2* <10 ms; or advanced liver disease as defined by persistent transaminases/direct bilirubin >3× ULN, coagulation abnormality >1.5× ULN attributable to liver disease, MRI evidence of cirrhosis, MRI findings suggestive of active hepatitis/significant fibrosis/inconclusive cirrhosis, or liver iron concentration ≥15 mg/g (and biopsy evidence when indicated, including cirrhosis, bridging fibrosis, or significant active hepatitis).

    Additional exclusion conditions include active clinically significant bacterial, viral, fungal, or parasitic infection; any prior or current malignancy except previously treated non–life‑threatening cured tumors; any prior or current immunodeficiency disorder; positive HIV‑1/2, detectable HBV DNA, detectable HTLV‑1/2, or detectable HCV viral load; >2 α‑globin gene deletions; inability to receive RBC transfusion; contraindication to plerixafor, busulfan, or anesthesia; an immediate family member with a known or suspected familial cancer syndrome; need for therapeutic anticoagulation during conditioning through platelet engraftment; clinically significant pulmonary hypertension requiring treatment or supplemental oxygen; pregnancy or breastfeeding; and a history of a significant bleeding disorder.

    BSWHP considers only one treatment per lifetime to be medically necessary. Repeat administration of lovotibeglogene autotemcel (Lyfgenia) is considered experimental and investigational because effectiveness of repeat dosing has not been established.

    Lovotibeglogene autotemcel for any indications not specifically listed in this policy is considered experimental and investigational and therefore not medically necessary, because effectiveness for other uses has not been established.

    Genotype Confirmation Requirements

    Confirmation of Sickle Cell Disease genotype is required when assessing eligibility for lovotibeglogene. Coverage is limited to the following genotypes confirmed by molecular or genetic testing:

    Required genotypes (one of)

    • βS/βS (homozygous sickle cell).
    • βS/β0 (sickle–β0 thalassemia).
    • βS/β+ (sickle–β+ thalassemia).
    Genotype confirmation must be documented in the medical record (molecular or genetic testing) prior to authorization.

    Coding

    Administration CPT CodesCPT
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
    HCPCS Codes (drug)HCPCSCovered
    J3394Injection, lovotibeglogene autotemcel, per treatment
    ICD-10 Codes (examples listed)ICD-10
    D57.00Hb-Ss Disease With Crisis, Unspecified
    D57.01Hb-Ss Disease With Acute Chest Syndrome
    D57.02Hb-Ss Disease With Splenic Sequestration
    D57.03Hb-Ss Disease With Cerebral Vascular Involvement
    D57.04Hb-Ss Disease With Dactylitis
    D57.09Hb-Ss Disease With Crisis With Other Specified Complication
    D57.1Sickle-Cell Disease Without Crisis
    D57.20Sickle-Cell/Hb-C Disease Without Crisis
    D57.211Sickle-Cell/Hb-C Disease With Acute Chest Syndrome
    D57.212Sickle-Cell/Hb-C Disease With Splenic Sequestration
    1–10 of 15
    1/2
    ICD-10 Codes (Sickle-Cell Thalassemia Beta Zero series)ICD-10
    D57.431Sickle-Cell Thalassemia Beta Zero With Acute Chest Syndrome
    D57.432Sickle-Cell Thalassemia Beta Zero With Splenic Sequestration
    D57.433Sickle-Cell Thalassemia Beta Zero With Cerebral Vascular Involvement
    D57.434Sickle-Cell Thalassemia Beta Zero With Dactylitis
    D57.438Sickle-Cell Thalassemia Beta Zero With Crisis With Other Specified Complication
    ICD-10 Codes (additional examples)ICD-10
    D57.44Sickle-Cell Thalassemia Beta Plus Without Crisis
    D57.451Sickle-Cell Thalassemia Beta Plus With Acute Chest Syndrome
    D57.452Sickle-Cell Thalassemia Beta Plus With Splenic Sequestration
    D57.453Sickle-Cell Thalassemia Beta Plus With Cerebral Vascular Involvement
    D57.454Sickle-Cell Thalassemia Beta Plus With Dactylitis
    D57.458Sickle-Cell Thalassemia Beta Plus With Crisis With Other Specified Complication
    D57.459Sickle-Cell Thalassemia Beta Plus With Crisis, Unspecified
    D57.80Other Sickle-Cell Disorders Without Crisis
    D57.811Other Sickle-Cell Disorders With Acute Chest Syndrome
    D57.812Other Sickle-Cell Disorders With Splenic Sequestration
    ICD-10 Codes (not covered example)ICD-10Not Covered
    D57.439Sickle-Cell Thalassemia Beta Zero With Crisis, Unspecified
    Severe vaso-occlusive events (sVOE) — eligibility threshold
    Required number of sVOEs>= 4 severe vaso-occlusive events in the prior 2 years
    TimeframeEvents occurred over the previous 2 years while receiving appropriate supportive care
    DocumentationClinical records supporting each sVOE (facility visit, treatments, transfusions, or diagnostic findings)
    Age — eligible member age range
    Minimum age>= 12 years
    Maximum age

    Provider Actions / Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for lovotibeglogene autotemcel (Lyfgenia); applicable procedure/administration HCPCS and infusion codes include J3394 (lovotibeglogene) and 96413 (infusion).

    Step Therapy

    Hydroxyurea failure/intolerance/contraindication required

    Member must have experienced hydroxyurea failure, intolerance, or have a documented contraindication prior to coverage of lovotibeglogene.

    Documentation Required

    Required documentation for prior authorization

    Eligibility Requirements

    Coverage for lovotibeglogene autotemcel (Lyfgenia) is available when all policy-level eligibility requirements are met. Key requirements include: member age between 12 and 50 years; prescription by or consultation with a board‑certified hematologist; documented contraindication to exagamglogene (Casgevy); confirmed SCD genotype of βS/βS, βS/β0, or βS/β+ by molecular or genetic testing; performance status of Karnofsky ≥60% for persons ≥16 years or Lansky ≥60% for persons <16 years; attestation that therapy will be delivered at an activated qualified treatment center; evidence of hydroxyurea failure, intolerance, or contraindication; eligibility for autologous HSCT and absence of an available HLA‑matched related donor; no prior HSCT, gene therapy, or investigational cellular therapy for SCD; adherence to FDA‑approved dosing and administration; and history of ≥4 severe vaso‑occlusive events in the prior 2 years while on appropriate supportive care.

    Requests must also demonstrate the member does not meet any exclusion conditions (laboratory thresholds, infections, malignancy, immunodeficiency, pregnancy/breastfeeding, family cancer syndrome, etc.) and that all required baseline organ assessments and labs meet the policy thresholds (ANC, platelets, LVEF, eGFR, ferritin and cardiac MRI T2*, liver assessment). Prior authorization is required and all requests are subject to review by a clinical pharmacist and medical director.

    For prior authorization, submit documentation that supports each eligibility criterion: contraindication to exagamglogene, board‑certified hematologist involvement, age, performance status, confirmed SCD genotype (βS/βS, βS/β0, or βS/β+), attestation of treatment at an activated qualified treatment center, hydroxyurea failure/intolerance/contraindication, eligibility for aHSCT and lack of an HLA‑matched related donor, clinical records documenting ≥4 severe vaso‑occlusive events in the prior 2 years, and baseline laboratory and organ assessment results meeting policy thresholds (including ANC, platelet count, LVEF, eGFR, ferritin/cardiac MRI T2*, and liver studies).

    Incomplete documentation or failure to meet ALL listed criteria may result in denial of the request.

    Not Covered

    Not covered: repeat administrations of lovotibeglogene autotemcel and use of lovotibeglogene for indications not described in this policy are considered experimental and investigational and are not medically necessary because effectiveness for these strategies has not been established.

    Background

    Background: Sickle cell disease (SCD) is an inherited single‑gene hemoglobin disorder characterized by red blood cell sickling, hemolysis, vaso‑occlusion, and multiorgan complications that shorten life expectancy. Lovotibeglogene autotemcel (Lyfgenia) is an autologous CD34+ hematopoietic stem cell‑based gene therapy intended as a one‑time administration for patients ≥12 years with SCD and a history of recurrent vaso‑occlusive events; it introduces a modified β‑globin gene (A‑T87Q) to produce anti‑sickling hemoglobin and reduce HbS polymerization.

    Definitions

    Severe vaso-occlusive episode (sVOE) — definition and examples
    DefinitionA severe vaso-occlusive episode (sVOE) is any of the listed acute SCD complications (see examples below)
    Acute pain eventPain requiring a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs) or RBC transfusion
    Acute chest syndromeNew pulmonary infiltrate with pneumonia-like symptoms, pain, or fever
    PriapismPriapism lasting >2 hours requiring a visit to a medical facility
    Splenic sequestrationEnlarged spleen, LUQ pain, and acute hemoglobin drop >= 2 g/dL
    Acute hepatic sequestrationSudden increase in liver size with RUQ pain, abnormal LFTs not due to biliary disease, and Hb drop >= 2 g/dL
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyLovotibeglogene autotemcel (Lyfgenia) — Medical Coverage Policy
    Policy CodePolicy 311
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewAug 11, 2025
    Next Review DateJun 25, 2027
    Key ActionObtain prior authorization and submit documentation confirming age, genotype, performance status, hydroxyurea failure/contraindication, sVOE history, treatment center attestation, and required labs.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions / RequirementsEligibility RequirementsNot CoveredBackgroundDefinitions
    <= 50 years
    Policy statementMember is 12 years of age or older, but less than or equal to 50 years of age
    Performance status — Karnofsky/Lansky thresholds
    Karnofsky threshold (>=16 years)Karnofsky performance status >= 60% for subjects >= 16 years of age
    Lansky threshold (<16 years)Lansky performance status >= 60% for subjects < 16 years of age
    DocumentationPerformance status must be documented in the medical record as meeting the stated threshold

    Submit documentation demonstrating all required eligibility elements, including contraindication to exagamglogene (Casgevy), board-certified hematologist prescribing or consult, age 12–50 years, performance status (Karnofsky ≥60% or Lansky ≥60%), confirmed SCD genotype (βS/βS, βS/β0, or βS/β+), attestation that therapy will be delivered at an activated qualified treatment center, hydroxyurea failure/intolerance/contraindication, eligibility for aHSCT and lack of an available HLA‑matched related donor, history of ≥4 sVOEs in the prior 2 years with supporting records, and absence of listed clinical/laboratory exclusions.

    Denial Risk

    Insufficient documentation or unmet criteria may result in denial

    Requests lacking prior authorization or sufficient documentation that the member meets ALL policy criteria (age, genotype, performance status, sVOE history, treatment center attestation, aHSCT eligibility and donor status, prior therapy history, and absence of exclusions) may be denied.

    Note

    Prescriber or consult must be a board‑certified hematologist

    Lovotibeglogene must be prescribed by or in consultation with a board‑certified hematologist.

    Activated qualified treatment center — attestation requirement
    Attestation requirementProvider must attest that lovotibeglogene will be administered at an activated qualified treatment center
    Who must attestPrescribing clinician (or responsible treating provider) as part of prior authorization documentation
    PurposeEnsures therapy delivery at a center that meets activation/qualification criteria for gene therapy administration